Company Profiles

driven by the PitchBook Platform

Regenesis Biomedical

Regenesis Biomedical
1996 FOUNDED
PRIVATE STATUS
51-200 EMPLOYEES
Series C LATEST DEAL TYPE
$5.2M LATEST DEAL AMOUNT
$15.7M TOTAL AMOUNT RAISED
Description

Developer of noninvasive regenerative medical products and services intended to improve the quality of life. The company's noninvasive regenerative medical products and services offer Provant Therapy System, which is a safe and non-drug pain management device, enabling users to avail medical products which can improve health for a more active and fulfilling life.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Services
Primary Office
5301 North Pima Road
Scottsdale, AZ 85250
United States

+1 (877) 970-4970
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Regenesis Biomedical’s full profile, request a free trial.

Regenesis Biomedical Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 10-Jun-2011 $5.2M $15.7M 000.00 Completed Profitable
5. Early Stage VC (Series B) 01-May-2008 00.000 000.00 000.00 Completed Profitable
4. Debt - General 01-May-2008 00000 00.000 Completed Profitable
3. Bridge 14-Jun-2005 00.000 00.000 Completed Profitable
2. Convertible Debt 09-Jun-2003 $825k $4.24M Completed Profitable
1. Early Stage VC (Series A) 03-Jun-2002 $3.42M $3.42M $14.3M Completed Profitable
To view this company’s complete deal history including valuation and funding request access »

Regenesis Biomedical Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00 00 00 00 00 00.000
Series A2 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A1 2,100,660 $0.001000 8% $0.58 $0.58 1x $0.58 7.47%
Series A 2,166,063 $0.001000 8% $1.58 $1.58 1x $1.58 7.71%
To view this company’s complete Cap Table request access »

Regenesis Biomedical Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Aztec Venture Network Venture Capital Minority 000 0000 000000 0
Desert Angels Angel Group Minority 000 0000 000000 0
Fulcrum Equity Partners Growth/Expansion Minority 000 0000 000000 0
Solstice Capital Venture Capital Minority 000 0000 000000 0
TGap Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Regenesis Biomedical Executive Team (10)

Name Title Board
Seat
Contact
Info
Scott Brooks Chief Executive Officer & Board Member
Dennis Genge Chief Financial Officer & Vice President
Art Loya Director, Engineering
Chris D'Errico Director of Sales, East
Frank George Co-Founder
You’re viewing 5 of 10 executives. Get the full list »

Regenesis Biomedical Board Members (9)

Name Representing Role Since Contact
Info
Henry Newman Solstice Capital Board Member 000 0000
Jack Ahrens II TGap Ventures Board Member 000 0000
John Xenos Regenesis Biomedical Board Member 000 0000
R. Nelson Self Board Member 000 0000
Richard Shirk Self Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 9 board members. Get the full list »